Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Hodgkin Disease 38Lymphoma 14Lymphoma, Large-Cell, Anaplastic 10Lymphoma, T-Cell 9Hematologic Diseases 8Lymphoma, Non-Hodgkin 7Lymphoma, T-Cell, Peripheral 6Lymphoma, Large B-Cell, Diffuse 5Mycosis Fungoides 4Lymphomatoid Papulosis 4Lymphoma, T-Cell, Cutaneous 4Enteropathy-Associated T-Cell Lymphoma 4Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Germ Cell and Embryonal 3Neoplasms 3Lymphoma, Primary Cutaneous Anaplastic Large Cell 3Lymphoma, B-Cell 3Lymphatic Diseases 3Immunoblastic Lymphadenopathy 3Testicular Neoplasms 2Sezary Syndrome 2Lymphoma, Follicular 2Leukemia 2Carcinoma, Embryonal 2Subcutaneous panniculitis-like T-cell lymphoma 1Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Nonseminomatous germ cell tumor 1Neoplasms by Histologic Type 1

Interventions

Rituximab 45Cyclophosphamide 34Doxorubicin 16fludarabine 14Prednisone 14Vincristine 13Etoposide 13ibrutinib 10Mycophenolic Acid 8Bortezomib 8Magnetic Resonance Spectroscopy 7Lenalidomide 7Cytarabine 7pembrolizumab 6Immunotherapy, Adoptive 6polatuzumab vedotin 5fludarabine phosphate 5Whole-Body Irradiation 5Vorinostat 5Tacrolimus 5Specimen Handling 5CT-P10 5obinutuzumab 4ibritumomab tiuxetan 4Nivolumab 4Ifosfamide 4Carmustine 4Carboplatin 4Antilymphocyte Serum 4tafasitamab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, B-Cell × Brentuximab Vedotin × Clear all
NCT01925612 2018-06-21

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Seagen Inc.

Phase 2 Terminated
87 enrolled 18 charts
Lymphoid

Hematologic Diseases, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01421667 2016-11-28

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Seagen Inc.

Phase 2 Completed
176 enrolled 30 charts
Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00365274 2014-06-02

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 3 charts
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡